Case Categories

Growth Strategies Case Study

IBS CDC IBS CDC IBS CDC IBS CDC RSS Feed
Case Title:

Merck In 2003

Publication Year : 2004

Authors: B N Renuka Prasad, G Srikanth

Industry: Health Care

Region:USA

Case Code: GRS0008

Teaching Note: Not Available

Structured Assignment: Not Available

Buy This Case Study
OR





Abstract:
In 1990s, Merck had a double-digit profit growth rate. Since 2001 its growth fell to single-digit as competitors merged and forged ahead. Analysts have predicted an earnings growth rate of just 2% for Merck against 8% to 10% for the industry between 2001 and 2006. In the face of a weak R&D pipeline and the loss of patent protection of several key products, Merck's pipeline for new drugs is poor when compared with its other counterparts. In this scenario will the company consider merging with other companies to improve its R&D pipeline, save costs and boost growth and thereby win the trust of its investors?

Pedagogical Objectives:

  • To highlight Merck's future R&D prospects
  • To discuss the strategic options for the company to regain its lost momentum.

Keywords : Merck & Co. Inc; Research and development; Growth Strategies Case Study; Blockbusters; United States pharmaceutical industry; GlaxoSmithKline Novartis Pfizer, Inc; Vioxx Cozaar Hyzaar; Big pharma companies; Mergers and acquisitions; New molecular entities; United States Food and Drug Administration; New drug application; Generic competition; Schering-Plough; Zocor Zetia

Contents : 
Introduction
Background
Merck’s R&D Pipeline
Merck’s Financial Highlights

Recently Bought Case Studies

    Recently Bought Case Studies
advertisement

    Executive Interviews

  • David ConklinDavid Conklin

    David Conklin, is a professor at the Richard Ivey School of Business
    Speaks on Government and Business
  • Lord Meghnad DesaiLord Meghnad Desai

    Lord Meghnad Desai, is an Indian-born British economist and Labor politician
    Speaks on Government and Business
  • Vijay GovindarajanVijay Govindarajan

    Vijay Govindarajan, is widely regarded as one of the world’s leading experts on strategy and innovation
    Speaks on Reverse Innovation
  • View All Executive Interviews»






Contact us: IBS Case Development Centre (IBSCDC), IFHE Campus, Donthanapally, Sankarapally Road, Hyderabad-501 504, Andhra Pradesh, INDIA.
Mob: +91- 9640901313, Phone: +91 - 08417 - 236672, Fax : + 91 - 08417 - 236674
E-mail: casehelpdesk@ibsindia.org

©2003-2010 IBS Case Development Centre. All rights reserved. | Careers | Privacy Policy | Terms of Use | Disclosure | Site Map xml sitemap